DCIS test registry to guide radiation and drug decisions
Part of Cancer, Skin clinical trials.
This study collects information from people with breast ductal carcinoma in situ (DCIS) to see how a specific lab test (DCISionRT) may help predict who benefits from radiation and/or certain medications. Your results and clinical details are gathered during routine care, not necessarily to change treatment right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed DCIS in one breast (other non-cancer findings like LCIS are allowed too)
- A DCISionRT test was ordered as part of your usual care
- You are planning for, or recently had, breast-conserving surgery (not a full breast removal for this DCIS)
- You can receive radiation and/or hormone or other systemic (whole-body) treatment if your team recommends it
- You are between 30 and 85 years old, and the DCIS tumor is under 6 cm
- Your DCIS diagnosis was within the last 120 days before you consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether removing the abnormal breast cells with breast-conserving surgery only (without additional treatment) is enough for people with low-risk ductal carcinoma in situ (DCIS). It may help some patients avoid extra treatments if their risk is very low.
This trial compares two approaches for ductal carcinoma in situ (DCIS): having surgery first versus getting radiation first and then having surgery later. It aims to see which plan controls DCIS better while affecting treatment timing and outcomes.
This trial tests whether doing a “sentinel lymph node biopsy” later (a delayed biopsy) can help assess whether cancer has spread to lymph nodes in people having a mastectomy for DCIS. It may help avoid unnecessary aggressive treatment if lymph nodes look normal.
This trial tests whether doing a sentinel lymph node biopsy later (after breast surgery) is a safe, accurate way to check if cancer has spread. It uses a special tracking shot that helps find the lymph nodes.
This study tests a decision-making tool to help people with newly diagnosed breast cancer make choices about removing the other (opposite) breast as a preventive step. It may help you think through risks and options in a clearer, more structured way.
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Hear when a new DCIS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.